Romero Lorca, AliciaNovillo Villajos, ApoloniaGaibar Alonso, MaríaGilsanz Muñoz, María FuencislaGalán Burgos, MiguelBeltrán, LauraAntón, BeatrizMalón, DiegoMoreno, AmaliaFernández Santander, Ana2026-02-032026-02-032021Romero-Lorca, A., Novillo, A., Gaibar, M., Gilsanz, M. F., Galán, M., Beltrán, L., Antón, B., Malón, D., Moreno, A., & Fernández-Santander, A. (2021). Mir-7, mir-10a and mir-143 expression may predict response to bevacizumab plus chemotherapy in patients with metastatic colorectal cancer. Pharmacogenomics and Personalized Medicine, Volume 14, 1263-1273. https://doi.org/10.2147/PGPM.S3135941178-7066https://hdl.handle.net/11268/16780Bevacizumab is a monoclonal antibody that binds to vascular endothelial growth factor A. It is currently used in combination with chemotherapy to treat metastatic colorectal cancer. This therapy is not equally effective in every patient; in some, mechanisms of resistance arise that remain poorly understood. The aim of the present work was to determine whether the expression of 26 miRNAs could be associated with the effectiveness of bevacizumab plus chemotherapy, with progression-free survival (PFS), and with overall survival (OS) in metastatic colorectal cancer.engAttribution-NonCommercial 4.0 Internationalhttp://creativecommons.org/licenses/by-nc/4.0/Neoplasias ColorrectalesAdhesión en ParafinaSupervivientes de Cáncerjournal article10.2147/PGPM.S313594open accessCáncerInvestigación médicaTecnología médicaGoal 3: Ensure healthy lives and promote well-being for all at all ages